Drug-Eluting Stent Wars Reach Standoff In Diabetic Patients
This article was originally published in The Gray Sheet
Executive Summary
The largest comparison to date of paclitaxel-versus sirolimus-eluting stents in diabetic patients failed to show a statistically significant difference in outcomes between the two devices, according to findings unveiled March 12 at the American College of Cardiology's annual meeting in Atlanta
You may also be interested in...
...and diabetes patients
Boston Scientific claims superior two-year results for Taxus compared to Cypher and bare-metal stents in a population of patients with diabetes, based on 708-patient registry data reported at the AHA Scientific Sessions Nov. 14. In the European T-Search/Research study, the target vessel revascularization rate was 9.7% for Taxus compared with 15.3% for Cypher and 19.5% for bare-metal stents. MACE (major adverse cardiac event) rates were 21.2% with Taxus, 28.9% with Cypher and 29.7% with bare-metal stents. Data from 1,182 diabetic patients in another Boston Scientific-sponsored registry reported earlier this year showed no statistically significant difference between the two drug-eluting products (1"The Gray Sheet" March 20, 2006, p. 4). Diabetics make up 25% of patients receiving coronary interventional procedures in the U.S., Boston Scientific says...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.